Skip to main content
Top
Published in: BMC Pediatrics 1/2020

01-12-2020 | IgA Vasculitis | Research article

Fecal calprotectin as a marker of gastrointestinal involvement in pediatric Henoch–Schönlein purpura patients: a retrospective analysis

Authors: Eun Young Paek, Dae Yong Yi, Ben Kang, Byung-Ho Choe

Published in: BMC Pediatrics | Issue 1/2020

Login to get access

Abstract

Background

Henoch–Schönlein purpura is a type of systemic vasculitis found in children. Its prognosis is usually good; however, recurrence is relatively common. If the intestines are affected, severe complications could arise. Here, we investigated the value of fecal calprotectin in the early screening of Henoch–Schönlein purpura and as a useful factor for predicting gastrointestinal manifestations.

Methods

We retrospectively reviewed the medical records of pediatric patients who were diagnosed with Henoch–Schönlein purpura and underwent fecal calprotectin testing during the acute phase. The patients were categorized into gastrointestinal involvement and non-gastrointestinal involvement groups based on their clinical symptoms. Moreover, gastrointestinal involvement was categorized as follows: upper gastrointestinal tract involvement (up to the duodenum) and lower gastrointestinal tract involvement (from the terminal ileum).

Results

A total of 69 patients were diagnosed with Henoch–Schönlein purpura and underwent fecal calprotectin testing. Among them, 40 patients (58.0%) showed signs of gastrointestinal involvement. The gastrointestinal involvement group had higher fecal calprotectin levels (379.9 ± 399.8 vs. 77.4 ± 97.6 mg/kg, P = 0.000). There were no significant differences in the recurrence of Henoch–Schönlein purpura symptoms or gastrointestinal symptoms. The cut-off value to identify gastrointestinal involvement was 69.10 mg/kg (P < 0.01). Patients with fecal calprotectin levels of > 50 mg/kg showed more frequent gastrointestinal involvement (77.8% vs. 20.8%, P = 0.000) and more severe gastrointestinal symptoms. Significant differences in abdominal pain duration, Henoch–Schönlein purpura clinical score, and abdominal pain severity were observed (P = 0.002, P = 0.000, and P = 0.000, respectively). Additionally, fecal calprotectin levels were significantly higher in patients with lower gastrointestinal tract involvement (214.67 ± 150.5 vs. 581.8 ± 510.1 mg/kg, P = 0.008), and the cut-off value was 277.5 mg/kg (P < 0.01).

Conclusion

Fecal calprotectin testing is useful for identifying gastrointestinal involvement in pediatric Henoch–Schönlein purpura patients.
Literature
1.
go back to reference Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11.CrossRef Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11.CrossRef
2.
go back to reference Davin JC, Coppo R. Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Schönlein purpura nephritis. Pediatr Nephrol. 2013;28:1897–903.CrossRef Davin JC, Coppo R. Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Schönlein purpura nephritis. Pediatr Nephrol. 2013;28:1897–903.CrossRef
3.
go back to reference Hwang HH, Lim IS, Choi BS, Yi DY. Analysis of seasonal tendencies in pediatric Henoch-Schönlein purpura and comparison with outbreak of infectious diseases. Medicine (Baltimore). 2018;97:e12217.CrossRef Hwang HH, Lim IS, Choi BS, Yi DY. Analysis of seasonal tendencies in pediatric Henoch-Schönlein purpura and comparison with outbreak of infectious diseases. Medicine (Baltimore). 2018;97:e12217.CrossRef
4.
go back to reference Reamy BV, Williams PM, Lindsay TJ. Henoch-Schönlein purpura. Am Fam Physician. 2009;80:697–704.PubMed Reamy BV, Williams PM, Lindsay TJ. Henoch-Schönlein purpura. Am Fam Physician. 2009;80:697–704.PubMed
5.
go back to reference Schwab J, Benya E, Lin R, Majd K. Contrast enema in children with Henoch-Schönlein purpura. J Pediatr Surg. 2005;40:1221–3.CrossRef Schwab J, Benya E, Lin R, Majd K. Contrast enema in children with Henoch-Schönlein purpura. J Pediatr Surg. 2005;40:1221–3.CrossRef
6.
7.
go back to reference Park Y, Son M, Jekarl DW, Choi HY, Kim SY, Lee S. Clinical significance of inflammatory biomarkers in acute pediatric diarrhea. Pediatr Gastroenterol Hepatol Nutr. 2019;22(4):369–76.CrossRef Park Y, Son M, Jekarl DW, Choi HY, Kim SY, Lee S. Clinical significance of inflammatory biomarkers in acute pediatric diarrhea. Pediatr Gastroenterol Hepatol Nutr. 2019;22(4):369–76.CrossRef
8.
go back to reference De Mattia D, Penza R, Giordano P, Del Vecchio GC, Aceto G, Altomare M, et al. von Willebrand factor and factor XIII in children with Henoch-Schonlein purpura. Pediatr Nephrol. 1995;9:603–5.CrossRef De Mattia D, Penza R, Giordano P, Del Vecchio GC, Aceto G, Altomare M, et al. von Willebrand factor and factor XIII in children with Henoch-Schonlein purpura. Pediatr Nephrol. 1995;9:603–5.CrossRef
9.
go back to reference Yilmaz D, Kavakli K, Ozkayin N. The elevated markers of hypercoagulability in children with Henoch-Schönlein purpura. Pediatr Hematol Oncol. 2005;22:41–8.CrossRef Yilmaz D, Kavakli K, Ozkayin N. The elevated markers of hypercoagulability in children with Henoch-Schönlein purpura. Pediatr Hematol Oncol. 2005;22:41–8.CrossRef
10.
go back to reference Kanik A, Baran M, Ince FD, Cebeci O, Bozkurt M, Cavusoglu D, et al. Faecal calprotectin levels in children with Henoch-Schönlein purpura: is this a new marker for gastrointestinal involvement? Eur J Gastroenterol Hepatol. 2015;27:254–8.PubMed Kanik A, Baran M, Ince FD, Cebeci O, Bozkurt M, Cavusoglu D, et al. Faecal calprotectin levels in children with Henoch-Schönlein purpura: is this a new marker for gastrointestinal involvement? Eur J Gastroenterol Hepatol. 2015;27:254–8.PubMed
11.
go back to reference Hong J, Yang HR. Laboratory markers indicating gastrointestinal involvement of Henoch-Schönlein purpura in children. Pediatr Gastroenterol Hepatol Nutr. 2015;18(1):39–47.CrossRef Hong J, Yang HR. Laboratory markers indicating gastrointestinal involvement of Henoch-Schönlein purpura in children. Pediatr Gastroenterol Hepatol Nutr. 2015;18(1):39–47.CrossRef
12.
go back to reference Jeoung SJ. The role of fecal calprotectin in pediatric disease. Korean J Pediatr. 2019;62(8):287–91.CrossRef Jeoung SJ. The role of fecal calprotectin in pediatric disease. Korean J Pediatr. 2019;62(8):287–91.CrossRef
13.
go back to reference Bonnín Tomàs A, Vila Vidal M, Rosell CA. Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease. Rev Esp Enferm Dig. 2007;99:689–93.CrossRef Bonnín Tomàs A, Vila Vidal M, Rosell CA. Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease. Rev Esp Enferm Dig. 2007;99:689–93.CrossRef
14.
go back to reference Ezri J, Nydegger A. Pediatrics. Fecal calprotectin in children: use and interpretation. Rev Med Suisse. 2011;7:69–70.PubMed Ezri J, Nydegger A. Pediatrics. Fecal calprotectin in children: use and interpretation. Rev Med Suisse. 2011;7:69–70.PubMed
15.
go back to reference Rodrigo L. Fecal calprotectin. Rev Esp Enferm Dig. 2007;99:683–8.PubMed Rodrigo L. Fecal calprotectin. Rev Esp Enferm Dig. 2007;99:683–8.PubMed
16.
go back to reference Jang HJ, Park JH, Kim CS, Lee SL, Lee WM. Amino acid-based formula in premature infants with feeding intolerance: comparison of fecal calprotectin level. Pediatr Gastroenterol Hepatol Nutr. 2018;21:189–95.CrossRef Jang HJ, Park JH, Kim CS, Lee SL, Lee WM. Amino acid-based formula in premature infants with feeding intolerance: comparison of fecal calprotectin level. Pediatr Gastroenterol Hepatol Nutr. 2018;21:189–95.CrossRef
17.
go back to reference Kim SY, Lee NM, Yun SW, Chae SA, Lim IS, Choi ES, et al. Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients. Korean J Pediatr. 2019;62(10):400–4.CrossRef Kim SY, Lee NM, Yun SW, Chae SA, Lim IS, Choi ES, et al. Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients. Korean J Pediatr. 2019;62(10):400–4.CrossRef
18.
go back to reference Höög CM, Bark LÅ, Broström O, Sjöqvist U. Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn’s disease. Scand J Gastroenterol. 2014;49:1084–90.CrossRef Höög CM, Bark LÅ, Broström O, Sjöqvist U. Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn’s disease. Scand J Gastroenterol. 2014;49:1084–90.CrossRef
19.
go back to reference Olsen PA, Fossmark R, Qvigstad G. Fecal calprotectin in patients with suspected small bowel disease—a selection tool for small bowel capsule endoscopy? Scand J Gastroenterol. 2015;50:272–7.CrossRef Olsen PA, Fossmark R, Qvigstad G. Fecal calprotectin in patients with suspected small bowel disease—a selection tool for small bowel capsule endoscopy? Scand J Gastroenterol. 2015;50:272–7.CrossRef
20.
go back to reference Teng X, Gao C, Sun M, Wu J. Clinical significance of fecal calprotectin for the early diagnosis of abdominal type of Henoch–Schonlein purpura in children. Clin Rheumatol. 2018;37:1667–73.CrossRef Teng X, Gao C, Sun M, Wu J. Clinical significance of fecal calprotectin for the early diagnosis of abdominal type of Henoch–Schonlein purpura in children. Clin Rheumatol. 2018;37:1667–73.CrossRef
21.
go back to reference Fagerberg UL, Loof L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr Actions. 2005;40:450–5.CrossRef Fagerberg UL, Loof L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr Actions. 2005;40:450–5.CrossRef
22.
go back to reference Montalto M, Santoro L, Dalvai S, Curigliano V, D'Onofrio F, Scarpellini E, et al. Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth. Dig Dis. 2008;26:183–6.CrossRef Montalto M, Santoro L, Dalvai S, Curigliano V, D'Onofrio F, Scarpellini E, et al. Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth. Dig Dis. 2008;26:183–6.CrossRef
23.
go back to reference Montalto M, Gallo A, Ianiro G, Santoro L, D'Onofrio F, Ricci R, et al. Can chronic gastritis cause an increase in fecal calprotectin concentrations? World J Gastroenterol Actions. 2010;16:3406–10.CrossRef Montalto M, Gallo A, Ianiro G, Santoro L, D'Onofrio F, Ricci R, et al. Can chronic gastritis cause an increase in fecal calprotectin concentrations? World J Gastroenterol Actions. 2010;16:3406–10.CrossRef
24.
go back to reference Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med. 2005;15:254–9.CrossRef Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med. 2005;15:254–9.CrossRef
Metadata
Title
Fecal calprotectin as a marker of gastrointestinal involvement in pediatric Henoch–Schönlein purpura patients: a retrospective analysis
Authors
Eun Young Paek
Dae Yong Yi
Ben Kang
Byung-Ho Choe
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2020
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-020-02263-x

Other articles of this Issue 1/2020

BMC Pediatrics 1/2020 Go to the issue